Filtered By:
Drug: Pradaxa
Nutrition: Vitamins

This page shows you your search results in order of relevance. This is page number 18.

Order by Relevance | Date

Total 482 results found since Jan 2013.

Analysis of the Cochrane Review: Direct Thrombin Inhibitors versus Vitamin K Antagonists for Preventing Cerebral or Systemic Embolism in People with Non-Valvular Atrial Fibrillation. Cochrane Database Syst Rev. 2014,3:CD009893.
Abstract Ischemic stroke is one of the most important complications of lone (non-valvular) atrial fibrillation. Its prevention is usually accomplished through oral anticoagulation. Until a few years ago warfarin was the most used agent, but recently two new pharmacologic classes have been introduced for stroke prevention in these patients: oral direct thrombin inhibitors (dabigatran and ximelagatran) and oral factor Xa inhibitors (rivaroxaban, apixaban and edoxaban). In this systematic review, oral direct thrombin inhibitors were compared with warfarin for efficacy and safety. The results indicate that there is no...
Source: Acta Medica Portuguesa - March 1, 2014 Category: Journals (General) Authors: Vaz Carneiro A, Costa J Tags: Acta Med Port Source Type: research

Dabigatran: patient management in specific clinical settings.
Abstract Dabigatran, a direct thrombin inhibitor, is licensed for the prevention of venous thromboembolism after knee and hip replacement, the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and for the treatment of acute venous thromboembolism. As dabigatran has a favourable benefit-risk profile, it is being increasingly used. Dabigatran differs from vitamin K antagonists as regards its pharmacological characteristics and its impact on certain laboratory tests, and also in the lack of a direct antagonist that can reverse dabigatran-induced anticoagulation. In emergency...
Source: Wiener Klinische Wochenschrift - August 20, 2014 Category: Journals (General) Authors: Kyrle PA, Binder K, Eichinger S, Függer R, Gollackner B, Hiesmayr JM, Huber K, Lang W, Perger P, Quehenberger P, Roithinger FX, Schmaldienst S, Weltermann A, Domanovits H Tags: Wien Klin Wochenschr Source Type: research

New oral anticoagulants in the prevention of thromboembolic complications in atrial fibrillation - a single-center experience.
Abstract Introduction:The prevention of thromboembolic complications in patients with atrial fibrillation(AF) takes priority in this group. In light of applicable guidelines, thesignificance of vitamin K antagonists (VKA) in stroke prevention decreased in favorofan ever more important role of new oral anticoagulants (nOAC). Theobjectives of this study are: theevaluation of the frequency of nOAC recommendations, the comparison between thepopulation of patients treatedwith VKA and those receiving nOAC, as well as theidentification of factors predisposing to the administration of nOAC to AF patients ondischarge.Metho...
Source: Polish Heart Journal - September 2, 2014 Category: Cardiology Authors: Gorczyca-Michta I, Wożakowska-Kapłon B Tags: Kardiol Pol Source Type: research

Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation
As atrial fibrillation (AF) substantially increases the risk of stroke and other thromboembolic events, most AF patients require appropriate antithrombotic prophylaxis. Oral anticoagulation (OAC) with either dose-adjusted vitamin K antagonists (VKAs) (eg, warfarin) or non-VKA oral anticoagulants (eg, dabigatran, apixaban, rivaroxaban) can be used for this purpose unless contraindicated. Therefore, risk assessment of stroke and bleeding is an obligatory part of AF management, and risk has to be weighed individually. Antiplatelet drugs (eg, aspirin and clopidogrel) are inferior to OAC, both alone and in combination, with a c...
Source: Cardiology Clinics - September 4, 2014 Category: Cardiology Authors: Mikhail S. Dzeshka, Gregory Y.H. Lip Source Type: research

Antiplatelet Properties of Oral Anticoagulants
Until recently, vitamin K antagonists (VKA) were the only oral anticoagulant drugs used in clinical practice for stroke or systemic embolism prevention in patients with non-valvular atrial fibrillation (AF). New oral anticoagulant drugs such as dabigatran etexilate and rivaroxaban have been developed and are currently available as an alternative in this indication. Both drugs were demonstrated to be non-inferior to warfarin for the prevention of stroke or systemic embolism in patients with non-valvular AF in the RE-LY and ROCKET trials [1,2].
Source: International Journal of Cardiology - December 23, 2014 Category: Cardiology Authors: Corinne Frère, Marc Laine, Franck Paganelli, Françoise Dignat-George, Laurent Bonello Tags: Letter to the Editor Source Type: research

Non-vitamin K antagonist oral anticoagulants in the cardioversion of patients with atrial fibrillation: systematic review and meta-analysis
Conclusions This systematic review and meta-analysis suggests that NOACs may be as safe as VKAs in the setting of AF cardioversion.
Source: Clinical Research in Cardiology - February 3, 2015 Category: Cardiology Source Type: research

Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
Abstract The effectiveness and safety of dabigatran for stroke prevention in atrial fibrillation (SPAF) demonstrated in RE-LY needs to be confirmed in daily care. To evaluate treatment persistence, effectiveness and safety of dabigatran therapy in SPAF patients in daily care, we used data from an ongoing, prospective, non-interventional registry of more than 2,500 patients on novel oral anticoagulants in daily care. Between October 1, 2011 and February 28, 2013, a total of 341 SPAF patients receiving dabigatran were enrolled. The combined endpoint of stroke/transient ischaemic attack/systemic embolism occurred at ...
Source: Thrombosis and Haemostasis - March 5, 2015 Category: Hematology Authors: Beyer-Westendorf J, Ebertz F, Förster K, Gelbricht V, Michalski F, Köhler C, Werth S, Endig H, Pannach S, Tittl L, Sahin K, Daschkow K, Weiss N Tags: Thromb Haemost Source Type: research

Clinical Significance of Non-Vitamin K Antagonist Oral Anticoagulants in the Management of Atrial Fibrillation.
Abstract Atrial fibrillation (AF) is the most commonly observed rhythm disorder in clinical practice. It is associated with a high risk of thromboembolic stroke and increased cardiovascular mortality. Vitamin K antagonists (VKAs), the only oral anticoagulants used for thromboembolic prophylaxis in AF patients over the past 60 years, have been effective in reducing thromboembolic stroke, compared with placebo and aspirin, in this group of patients. However, VKAs have a very narrow therapeutic window, so regular monitoring of the therapeutic effect is obligatory for their use. The need for regular assessment of bloo...
Source: Circulation Journal - April 2, 2015 Category: Cardiology Authors: Santarpia G, Curcio A, Sibilio G, Indolfi C Tags: Circ J Source Type: research

Outcomes After Cardioversion in Atrial Fibrillation Patients Treated with Non-Vitamin K Antagonist Oral Anticoagulants (NOACs): Insights from a Meta-Analysis
Conclusions Data from patients enrolled in RCTs, showed that NOACs are effective and safe for AF patients undergoing cardioversion.
Source: American Journal of Cardiovascular Drugs - July 2, 2015 Category: Cardiology Source Type: research

Use of non‐vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic
ConclusionIn this specialist AF clinic, patients prescribed NOACs had a favourable adverse event profile with good efficacy for stroke prevention, with a low rate of cessation or switch to warfarin.
Source: International Journal of Clinical Practice - August 3, 2015 Category: Internal Medicine Authors: S. I. Lee, M. Sayers, G. Y. H. Lip, D. A. Lane Tags: Original Paper Source Type: research

Early-Phase NOAC, VKA Therapy: Similar Bleeding, Stroke Risk Early-Phase NOAC, VKA Therapy: Similar Bleeding, Stroke Risk
Thus, physicians must be just as cautious when initiating dabigatran or rivaroxaban as when initiating a vitamin-K agonist, the authors of this French nationwide cohort study say. Heartwire from Medscape
Source: Medscape Medical News Headlines - August 6, 2015 Category: Consumer Health News Tags: Cardiology News Source Type: news

Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study.
In conclusion, persistence was significantly higher with NOAC than VKA, and could alone lead to reduced cardioembolic strokes. Increased guideline adherence following NOAC introduction could further decrease AF stroke burden. PMID: 26246112 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - August 6, 2015 Category: Hematology Authors: Martinez C, Katholing A, Wallenhorst C, Freedman SB Tags: Thromb Haemost Source Type: research

Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation.
Abstract The non-vitamin K antagonist oral anticoagulants (NOACs) are replacing warfarin for stroke prevention in many patients with nonvalvular atrial fibrillation. Edoxaban, an oral factor Xa inhibitor, is the newest entrant in this class. Results of the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation (ENGAGE AF) study demonstrate that edoxaban is noninferior to warfarin for prevention of stroke and systemic embolic events, and is associated with significantly less major bleeding, including intracranial bleeding, and reduced cardiovascular mortality. With a net clinical benefit ov...
Source: Thrombosis and Haemostasis - October 15, 2015 Category: Hematology Authors: Weitz JI, Eikelboom J Tags: Thromb Haemost Source Type: research

Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation
As atrial fibrillation (AF) substantially increases the risk of stroke and other thromboembolic events, most AF patients require appropriate antithrombotic prophylaxis. Oral anticoagulation (OAC) with either dose-adjusted vitamin K antagonists (VKAs) (eg, warfarin) or non-VKA oral anticoagulants (eg, dabigatran, apixaban, rivaroxaban) can be used for this purpose unless contraindicated. Therefore, risk assessment of stroke and bleeding is an obligatory part of AF management, and risk has to be weighed individually. Antiplatelet drugs (eg, aspirin and clopidogrel) are inferior to OAC, both alone and in combination, with a c...
Source: Heart Failure Clinics - March 9, 2016 Category: Cardiology Authors: Mikhail S. Dzeshka, Gregory Y.H. Lip Source Type: research